Phathom Pharmaceuticals Inc — movimiento trimestral de fondos (NASDAQ:PHAT) | MetaTrader

Ver el calendario completo

Financials

Visión general Informes Estadísticas

Activos totales 378.32 M294.21 M250.22 M240.29 M259.15 M Total de pasivos 631.9 M632.58 M656.05 M662.82 M697.32 M Capital total -253.58 M-338.38 M-405.83 M-422.53 M-438.17 M Total de pasivos y patrimonio neto 378.32 M294.21 M250.22 M240.29 M259.15 M Deuda total 201.41 M203.25 M205.14 M207.09 M209.09 M Deuda neta -95.85 M-9.07 M55.57 M71.94 M79.11 M

Noticias

Rocket Pharmaceuticals y Argan suben en el premercado; Two Harbors baja

Barclays mejora la calificación de Phathom Pharmaceuticals por perspectivas de ingresos

Ocugen Falls as Gene Therapy for Eye Disease Lags in Phase II Study

ImmunityBio Rises on China Nod to Bladder Cancer Combo Therapy

Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why

Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli

COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM

Phathom Pharmaceuticals, Inc. (PHAT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2025 Earnings Call Transcript

Stifel reitera Comprar en acciones de Phathom, mantiene precio objetivo de 28 dólares

Stifel reitera Compra en Phathom con precio objetivo de $28